FDA Advisers Reject Nuplazid for Alzheimer’s Disease Psychosis
An FDA advisory panel rejected pimavanserin (Nuplazid) for the treatment of hallucinations and delusions in patients with Alzheimer’s disease psychosis on Friday. In a vote of 9-3, the Psychopharmacologic Drugs Advisory Committee decided against recommending the drug for approval for these patients, citing a slew of shortcomings in supporting trial data. This could have been […]